Trial Profile
The efficacy of tolvaptan in a population with congestive heart failure and chronic kidney disease: A multicenter, randomized, open label, blind endpoint study (AQUAKID-Study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Furosemide
- Indications Heart failure; Kidney disorders
- Focus Therapeutic Use
- Acronyms AQUAKID
- 13 Oct 2013 New trial record